Joining us for the first time on The Daily Dive today is that of Trevor Peters, CEO of Willow Biosciences (TSX: WLLW). Trevor joins host Cassandra Leah this morning to discuss the unique business of cannabinoid manufacturing.
Willow Biosciences is a biotech firm focused on producing high purity cannabinoids for the treatment of a number of ailments. Its competitive edge for the market is focused around the method of production of cannabinoids, which does not occur via the traditional method of growing a plant. Instead, the firm biosynthesizes the compound via a yeast host, to produce a consistent, scalable and sustainable product. Presently, the firm is focused on the production of ultra-pure cannabigerol, or CBG, which it expects to commercialize in the current quarter.
Catch the full interview with Trevor below.
FULL DISCLOSURE: Willow Biosciences Inc is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Willow Biosciences Inc on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
